Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy

Inclusion Criteria: * Confirmed histological diagnosis of breast cancer Receiving first-line AC chemotherapy (doxorubicin + cyclophosphamide) Age 18 years or older Female sex Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Adequate bone marrow function (absolute neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L) Adequate hepatic function (transaminases ≤ 2.5 × upper limit of normal) Adequate renal function (creatinine ≤ 1.5 × upper limit of normal) Normal cardiac function (left ventricular ejection fraction ≥ 50%) Willing and able to provide written informed consent Exclusion Criteria: * Previous chemotherapy or radiotherapy for breast cancer History of other malignant neoplasms (except non-melanoma skin cancer or carcinoma in situ of the cervix) Severe organ dysfunction (cardiac, hepatic, renal, pulmonary) Active infection requiring systemic therapy Known hypersensitivity to Naderin or any of its components Known hypersensitivity to doxorubicin, cyclophosphamide, or any excipients Pregnancy or breastfeeding Psychiatric or cognitive impairment that would interfere with study participation Participation in another interventional clinical trial within 30 days prior to enrollment Any condition that, in the investigator's opinion, would compromise participant safety or interfere with study objectives